Defendant

Cobalt Laboratories

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
—
Top venue
S.D. Indiana
1 case

Company profile

Cobalt Laboratories (U.S. entity originally incorporated as Cobalt Laboratories, Inc.; a Cobalt Laboratories, LLC is currently registered in Florida) is a generic pharmaceutical company. It was the U.S. arm of Cobalt Pharmaceuticals Inc. of Mississauga, Ontario, one of Canada's larger generic drugmakers and part of the privately held Arrow Group. A 2010 FTC complaint lists Cobalt Laboratories, Inc.'s principal place of business as Bonita Springs, Florida. Florida corporate records now show Cobalt Laboratories, LLC with a registered office at 400 Interpace Parkway, Parsippany, New Jersey, and Watson Laboratories, Inc. as its sole member.

Operations. Cobalt developed, manufactured, and marketed generic prescription pharmaceuticals in the U.S., distributing directly and through affiliates and agents. Identified activities include an ANDA for generic duloxetine HCl (Cymbalta), an ANDA for cabergoline (Dostinex), a pending ANDA for dronabinol (Marinol) later divested to Impax, and manufacture and sale of generic alendronate sodium tablets (Fosamax). Revenue, headcount, and founding year are not verified by the sources reviewed.

Ownership. Watson Pharmaceuticals acquired the Arrow Group, including Cobalt, for approximately $1.75 billion; the deal closed December 2, 2009 after an FTC consent order required divestiture of the cabergoline and dronabinol ANDAs to Impax. Watson Pharmaceuticals later became Actavis and was acquired by Teva Pharmaceutical Industries in 2016, so the Cobalt entity sits within Teva's generics organization. It is not publicly traded.

Litigation posture. Cobalt is an operating company, not a patent assertion entity: the tracked data show 0 plaintiff cases and 1 defendant case. The sole tracked matter, Eli Lilly and Company v. Cobalt Laboratories, No. 1:08-cv-01550 (S.D. Ind., filed November 14, 2008), is Hatch-Waxman/Paragraph IV litigation in which Lilly sought rulings that its duloxetine patents were valid and infringed; Lilly filed parallel actions against several other generic filers in the same court, which is Lilly's home venue rather than a plaintiff-friendly patent venue. Cobalt has also been named in Boniva (ibandronate) patent litigation and in alendronate product-liability suits as a Watson affiliate.